

Supplementary Table 1: List of the adverse events (Grade  $\geq 3$ ) which were observed in the ICORG08-10 study of 106 patients.

	Adverse Event (Grade $\geq 3$ )	n (%) – total 106 patients
Gastrointestinal disorders	Diarrhoea	6
	Abdominal Pain	2
	Stomatitis	1
	Constipation	1
	Vomiting	1
	Nausea	1
	Anal Fistula	1
	Gastrointestinal perforation	1
	Intestinal perforation	1
General disorders and administration site disorders	Fatigue	5
	Chest pain	1
	Adverse drug reaction	1
	Injection site pain	1
Musculoskeletal and connective tissue disorders	Artralgia	6
	Back Pain	5
	Bone pain	1
	Pain in extremity	1
	Musculoskeletal pain	1
	Musculoskeletal stiffness	1
Skin and subcutaneous tissue disorder	Rash	1
	Skin reaction	1
	Rash pruritic	1
Nervous system disorders	Headache	2
	Neuropathy peripheral	2
	Dizziness	1
	Syncope	1
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	1
	Cough	1
	Dysphonia	1
Vascular disorders	Hypertension	26
	Hot flush	1
	Lymphoedema	1
Infections and infestations	Neutropenic Sepsis	3
	Cellulitis	2
	Lower respiratory tract infection	1
	Vulvovaginal candidiasis	1
	Localised infection	1
	Sinusitis	1
	Breast cellulitis	1
	Catheter site infection	1
	Incision site cellulitis	1
	Neutropenic infection	1
	Pneumonia	1
Investigations	$\gamma$ -glutamyltransferase increased	2
	Weight increased	1
	c-reactive protein increased	1
	White blood cell count decreased	1
Injury poisoning and procedural complications	Overdose	1
Renal and urinary disorders	Proteinuria	3
	Neutropenia	7

Blood and lymphatic system disorders	Febrile neutropenia	1
	Lymphopenia	1
	Lymphadenopathy	1
Immune system disorders	Hypersensitivity	3
	Autoimmune disorders	1

Supplementary Table 4: Baseline, Follow-up and Fold Changes in Biomarker Levels as predictors of CT

Predictor		CT (N=12)	NCT (N=48)	Difference in Means* (95% CI)	P-value
Baseline	MPO	0.51	0.77	-0.26 (-0.62, 0.11)	0.1370
	PIGF	170.77	156.66	14.11 (-44.14, 72.35)	0.5242
	cTnI	4.44	4.54	-0.10 (-1.31, 1.12)	0.8523
	VEGF	323.57	391.84	-68.27 (-273.4, 136.87)	0.4643
Follow-up (Month indicated)	MPO (3)	0.85	0.96	-0.104 (-0.72, 0.51)	0.6747
	PIGF (3)	124.3	149.33	-25.03 (-89.51, 39.45)	0.4774
	cTnI (3)	4.85	5.41	-0.57 (-1.96, 0.82)	0.2087
	VEGF (6)	92.1	24.36	67.739 (2.79, 132.69)	0.4584
Change from baselinet (Month indicated)	MPO (3)	0.87	0.29	0.57 (-0.19, 1.34)	0.1637
	PIGF (3)	-0.91	-0.19	-0.73 (-1.67, 0.22)	0.2425
	cTnI (3)	0.18	0.30	-0.12 (-0.47, 0.23)	0.4285
	VEGF (6)	-3.68	-4.28	0.59 (-2.71, 3.89)	0.6292

MPO = Myeloperoxidase, PIGF = Placental Growth Factor, cTnI = Cardiac Troponin I, VEGF = Vascular Endothelial Growth Factor

\*Differences in means between follow-up and baseline biomarker levels in the CT versus NCT groups compared using two-sample t-tests

† The log -2 fold change ratio of follow-up (month indicated) to baseline biomarker levels

